Evidence map›Paper›PMID 40155991›Full record

ArticleJournal of translational medicine2025

Machine learning models for predicting metabolic dysfunction-associated steatotic liver disease prevalence using basic demographic and clinical characteristics.

Gangfeng Zhu, Yipeng Song, Zenghong Lu, Qiang Yi, Rui Xu, Yi Xie, Shi Geng, Na Yang, Liangjian Zheng, Xiaofei Feng and 4 more

Abstract read
In one paragraph

Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Gangfeng ZhuThe First Clinical Medical College, Gannan Medical University, Ganzhou, Jiangxi Province, 341000, China.
Yipeng SongThe First Clinical Medical College, Gannan Medical University, Ganzhou, Jiangxi Province, 341000, China.
Zenghong LuJiangxi Clinical Research Center for Cancer, Department of Oncology, The First Affiliated Hospital, Gannan Medical University, Ganzhou, Jiangxi Province, 341000, China.
Qiang YiThe First Clinical Medical College, Gannan Medical University, Ganzhou, Jiangxi Province, 341000, China.
Rui XuDepartment of Rehabilitation Medicine, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, Zhejiang Province, 321000, China.
Yi XieThe First Clinical Medical College, Gannan Medical University, Ganzhou, Jiangxi Province, 341000, China.
Shi GengArtificial Intelligence Unit, Department of Medical Equipment Management, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Na YangArtificial Intelligence Unit, Department of Medical Equipment Management, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Liangjian ZhengThe First Clinical Medical College, Gannan Medical University, Ganzhou, Jiangxi Province, 341000, China.
Xiaofei FengJiangxi Clinical Research Center for Cancer, Department of Oncology, The First Affiliated Hospital, Gannan Medical University, Ganzhou, Jiangxi Province, 341000, China.
Rui ZhuJiangxi Clinical Research Center for Cancer, Department of Oncology, The First Affiliated Hospital, Gannan Medical University, Ganzhou, Jiangxi Province, 341000, China.
Xiangcai WangJiangxi Clinical Research Center for Cancer, Department of Oncology, The First Affiliated Hospital, Gannan Medical University, Ganzhou, Jiangxi Province, 341000, China. wangxiangcai@csco.ac.cn.
Li HuangJiangxi Clinical Research Center for Cancer, Department of Oncology, The First Affiliated Hospital, Gannan Medical University, Ganzhou, Jiangxi Province, 341000, China. hlellen@gmu.edu.cn.
Yi XiangJiangxi Clinical Research Center for Cancer, Department of Oncology, The First Affiliated Hospital, Gannan Medical University, Ganzhou, Jiangxi Province, 341000, China. xiangyi_xiangyi@126.com.ORCID http://orcid.org/0000-0002-8969-7371

Funding

Doctoral research Foundation of the First Affiliated Hospital of Gannan Medical University QD095
6 · The paper itself

Abstract

backgroundMetabolic dysfunction-associated steatotic liver disease (MASLD) is a global health concern that necessitates early screening and timely intervention to improve prognosis. The current diagnostic protocols for MASLD involve complex procedures in specialised medical centres. This study aimed to explore the feasibility of utilising machine learning models to accurately screen for MASLD in large populations based on a combination of essential demographic and clinical characteristics.

methodsA total of 10,007 outpatients who underwent transient elastography at the First Affiliated Hospital of Gannan Medical University were enrolled to form a derivation cohort. Using eight demographic and clinical characteristics (age, educational level, height, weight, waist and hip circumference, and history of hypertension and diabetes), we built predictive models for MASLD (classified as none or mild: controlled attenuation parameter (CAP) ≤ 269 dB/m; moderate: 269-296 dB/m; severe: CAP > 296 dB/m) employing 10 machine learning algorithms: logistic regression (LR), multilayer perceptron (MLP), extreme gradient boosting (XGBoost), bootstrap aggregating, decision tree, K-nearest neighbours, light gradient boosting machine, naive Bayes, random forest, and support vector machine. These models were externally validated using the National Health and Nutrition Examination Survey (NHANES) 2017-2023 datasets.

resultsIn the hospital outpatient cohort, machine learning algorithms demonstrated robust predictive capabilities. Notably, LR achieved the highest accuracy (ACC) of 0.711 in the test cohort and 0.728 in the validation cohort, coupled with robust areas under the receiver operating characteristic curve (AUC) values of 0.798 and 0.806, respectively. Similarly, MLP and XGBoost showed promising results, with MLP achieving an ACC of 0.735 in the test cohort, and XGBoost registering an AUC of 0.798. External validation using the NHANES datasets yielded consistent AUC results, with LR (0.831), MLP (0.823), and XGBoost (0.784) performing robustly.

conclusionsThis study demonstrated that machine learning models constructed using a combination of essential demographic and clinical characteristics can accurately screen for MASLD in the general population. This approach significantly enhances the feasibility, accessibility, and compliance of MASLD screening and provides an effective tool for large-scale health assessments and early intervention strategies.

Indexed as

DemographyFatty LiverMachine LearningMetabolic DiseasesAdultAgedFemaleHumansMaleMiddle AgedPrevalenceReproducibility of ResultsROC CurveDemographic and clinical characteristicsMachine learningMetabolic dysfunction-associated steatotic liver diseaseNational health and nutrition examination surveyNon-invasive screening

Identifiers

PMID40155991
PMCPMC11951774

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.